Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Guardant Health (NASDAQ:GH) and raises the price target from $30 to $38.
June 04, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Kyle Mikson maintains a Buy rating on Guardant Health and raises the price target from $30 to $38.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100